|
|
|
|
| Explore the evolving role of exosomes and extracellular vesicles (EVs) at the next Cell & Gene Live. Chief Editor Erin Harris moderates a discussion with Capricor’s Linda Marbán and Aegle’s Dr. Gloria Matthews on clinical and commercial advances, including applications in rare and cardiovascular diseases. Gain insights into the future of exosome-based therapies from leaders driving innovation across R&D, manufacturing, and commercialization. |
|
|
FOCUS ON REGULATORY & COMPLIANCE |
|
|
|
By Melissa Beiner, M.D., Senior Director of R&D, Biohaven Pharmaceuticals | Spinocerebellar ataxia (SCA) is a rare, progressive, and fatal neurodegenerative disease with no approved treatments, but Biohaven Pharmaceuticals’ new drug troriluzole — designed to modulate glutamate and slow disease progression — has shown promise in clinical trials and is currently under FDA review, offering hope to patients and families facing this devastating disorder. | |
|
|
|
|
|
|
|
|
REGULATORY & COMPLIANCE SOLUTIONS |
|
|
|
|
|
|
|
| With pressure to both accelerate development and prioritize robustness, CGT companies often have limited time for refining manufacturing, analytics, and logistics. Enter the Cell & Gene Therapy Tech Expo: a dynamic slate of industry-leading suppliers showcasing the latest in solutions across Cell Therapy, Gene Therapy, and GMP/Regulatory Compliance via 15-minute interactive presentations. Register for free and make continuous improvement a reality on your path to scalability, cost reduction and, ultimately, enhanced patient access. |
|
|
| Connect With Cell & Gene: |
|
|
|
